RxDoctor Payments Data

Shazia Hamid, MD

Internal Medicine · Las Vegas, NVNPI 1811955214

Payments from drug & device makers

$2,766in general payments, 2019–2025

Across 150 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$488
  • Amgen$405
  • Novo Nordisk$352
  • Almatica Pharma LLC$211
  • Idorsia Pharmaceuticals US Inc$194
  • Genentech USA, Inc.$160
  • plus $957 from 16 others

What the payments were for

  • Food & beverage$2,766100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,766 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$166,921
Medicare patients
176
Services billed
1,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$88,726
MounjaroTirzepatide21$21,878
FarxigaDapagliflozin Propanediol17$15,066
JanuviaSitagliptin Phosphate11$11,017
JardianceEmpagliflozin17$10,088
QuviviqDaridorexant Hcl21$9,950
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav165$1,345
Albuterol Sulfate HfaAlbuterol Sulfate46$1,256
Pregabalin42$1,230
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort18$959
Levothyroxine Sodium65$683
Rosuvastatin Calcium52$608
Losartan Potassium129$585
Metoprolol Succinate54$531
Amlodipine Besylate119$498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$352$88,72692 claims
Lilly USA, LLCMounjaro$121$21,87821 claims
AstraZenecaFarxiga$488$15,06617 claims
Idorsia Pharmaceuticals US IncQuviviq$194$9,95021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →